As a matter of fact, the true revolution that is presently occurring in cancer therapy thanks to the broad clinical efficacy of antagonist antibodies to CTLA-4, PD-1 and PD-L1 is actually unraveling the potency that antitumor immune responses can reach if appropriately unleashed [2]. The gene discussed is CD274; the disease is cancer.